A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.
Esther Natalie Olíva, Sarah M. Ronnebaum, Omer Zaidi, Dipen Patel, Salem Abi Nehme, Clara Chen, António Almeida
Abstract
AML across multiple instruments, and lower health utility values versus other AML health states (i.e. newly diagnosed, remission, consolidation, and maintenance therapy). The clinical efficacy SLR identified 50 trials (66 total trial arms). CR/CRi rates and mOS have remained relatively stable and low over the last 2 decades. Across all arms, the median rate of CR/CRi was 18.3% and mOS was 6.2 months. In conclusion, a substantial proportion of patients with AML will develop RR AML, which is associated with significant humanistic and economic burden. Existing treatments offer limited efficacy, highlighting the need for more effective non-intensive treatment options.